Grufity logoGrufity logo

Personalis Inc Stock Research

PSNL

2.60USD-0.11(-4.06%)Market Closed

Market Summary

USD2.60-0.11
Market Closed
-4.06%

PSNL Stock Price

PSNL RSI Chart

PSNL Valuation

Market Cap

121.4M

Price/Earnings (Trailing)

-1.07

Price/Sales (Trailing)

1.87

EV/EBITDA

-0.31

Price/Free Cashflow

-1.01

PSNL Price/Sales (Trailing)

PSNL Profitability

Operating Margin

20.52%

EBT Margin

-174.14%

Return on Equity

-51.95%

Return on Assets

-38.71%

Free Cashflow Yield

-98.92%

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

65.0M

Revenue Y/Y

-19.15%

Revenue Q/Q

12.55%

PSNL Earnings

Earnings (TTM)

-113.3M

Earnings Y/Y

-53.81%

Earnings Q/Q

-17.27%

Price Action

52 Week Range

1.738.96
(Low)(High)

Last 7 days

-10.3%

Last 30 days

-18.2%

Last 90 days

33.3%

Trailing 12 Months

-68.4%

PSNL Financial Health

Current Ratio

6.03

PSNL Investor Care

Shares Dilution (1Y)

4.01%

Diluted EPS (TTM)

-2.48

Peers (Alternatives to Personalis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.9B
6.8B
-7.12% -2.94%
31.04
5.68
8.37% 3.64%
35.0B
14.4B
-10.73% -16.15%
32.06
2.43
3.86% 12.94%
34.8B
4.6B
9.07% -35.87%
-7.89
7.58
1.28% -677.95%
9.9B
4.0B
-11.55% -31.05%
20.3
2.48
12.31% 24.36%
MID-CAP
5.7B
1.5B
-7.14% 13.35%
23.05
3.87
27.80% 34.93%
3.6B
5.4B
-7.30% -56.29%
13.33
0.66
3.46% 13.48%
SMALL-CAP
2.2B
128.3M
3.11% -0.62%
-6.93
16.97
-1.69% -73.40%
1.2B
185.3M
-4.53% -36.18%
-6.03
6.51
20.06% 3.42%
597.7M
137.0M
-4.54% -49.04%
-8.9
4.36
45.65% -114.55%
316.8M
516.3M
-37.38% -84.33%
-0.1
0.61
12.13% -719.59%
255.3M
138.6M
-29.45% -81.04%
-7.6
1.84
32.30% -57.86%
121.4M
65.0M
-18.24% -68.45%
-1.07
1.87
-23.92% -73.73%

Financials for Personalis

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-5.7%65,047,00069,007,00076,410,00079,840,00085,494,000
  S&GA Expenses6.9%63,969,00059,850,00057,209,00052,763,00047,698,000
  R&D Expenses3.3%64,912,00062,855,00061,515,00056,914,00049,312,000
EBITDA-10.0%-104,642,000-95,129,000-86,666,000-74,450,000-
EBITDA Margin-16.7%-1.61-1.38-1.13-0.93-
Earnings Before Taxes-10.6%-113,275,000-102,417,000-93,594,000-81,007,000-65,212,000
EBT Margin-17.3%-1.74-1.48-1.22-1.01-
Interest Expenses-5.6%201,000213,000228,000243,000184,000
Net Income-10.6%-113,315,000-102,446,000-93,624,000-81,031,000-65,226,000
Net Income Margin-17.3%-1.74-1.48-1.23-1.01-
Free Cahsflow-6.6%-120,129,000-112,680,000-97,343,000-89,720,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-7.9%293318358381397
  Current Assets-10.0%200222260294318
    Cash Equivalents6.7%89.0084.0087.0092.00106
  Net PPE1.2%62.0061.0048.0031.0020.00
Liabilities-1.2%75.0075.0093.0094.0086.00
  Current Liabilities-1.8%33.0034.0042.0040.0031.00
Shareholder's Equity-10.0%218242265287310
  Retained Earnings-9.4%-360-329-302-275-247
  Additional Paid-In Capital1.1%579573569563558
Accumulated Depreciation7.5%24.0023.0021.0019.00-
Shares Outstanding1.6%47.0046.0046.0045.0045.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-2.2%-70.23-68.74-71.86-70.44-70.83
  Share Based Compensation9.9%19.0018.0017.0016.0014.00
Cashflow From Investing-25.6%53.0071.0089.0019.00-60.07
Cashflow From Financing-38.0%1.002.001.007.00170

Risks for PSNL

What is the probability of a big loss on PSNL?

99.0%


Probability that Personalis stock will be more than 20% underwater in next one year

97.5%


Probability that Personalis stock will be more than 30% underwater in next one year.

96.0%


Probability that Personalis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PSNL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Personalis was unfortunately bought at previous high price.

Drawdowns

Returns for PSNL

Cumulative Returns on PSNL

-26.4%


3-Year Cumulative Returns

Which funds bought or sold PSNL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-33.6
-42,000
34,000
-%
2023-02-15
Bruce & Co., Inc.
new
-
99,000
99,000
0.03%
2023-02-15
Wellington Shields Capital Management, LLC
reduced
-11.51
-1,187,990
1,709,010
0.21%
2023-02-15
Wellington Shields & Co., LLC
added
9.39
-744,640
2,006,360
0.46%
2023-02-15
JANE STREET GROUP, LLC
reduced
-20.38
-43,397
49,603
-%
2023-02-15
Steward Partners Investment Advisory, LLC
unchanged
-
198
198
-%
2023-02-15
Financial Gravity Asset Management, Inc.
new
-
8.00
8.00
-%
2023-02-15
B. Riley Asset Management, LLC
new
-
248,827
248,827
0.11%
2023-02-14
Point72 Hong Kong Ltd
sold off
-100
-
-
-%
2023-02-14
LMR Partners LLP
sold off
-100
-51,000
-
-%

1–10 of 49

Latest Funds Activity

Are funds buying PSNL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own PSNL
No. of Funds

Personalis News

Business Wire

Personalis Announces Four Abstracts Accepted for Presentation at ....

Business Wire,
4 days ago

Defense World

Yahoo Finance

Yahoo Finance

InvestorsObserver

Silicon Valley Business Journal

Schedule 13G FIlings of Personalis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 31, 2023
blackrock inc.
7.7%
3,558,913
SC 13G/A
Jan 25, 2023
jpmorgan chase & co
7.6%
3,502,353
SC 13G/A
Mar 09, 2022
blackrock inc.
10.0%
4,502,224
SC 13G/A
Mar 07, 2022
lightspeed venture partners viii lp
9.16%
4,117,768
SC 13D/A
Feb 09, 2022
ark investment management llc
10.91%
4,888,115
SC 13G/A
Feb 03, 2022
blackrock inc.
9.8%
4,389,333
SC 13G/A
Jan 14, 2022
jpmorgan chase & co
9.5%
4,267,659
SC 13G/A
Feb 16, 2021
abingworth llp
0.0%
0
SC 13G/A
Feb 02, 2021
blackrock inc.
5.9%
2,309,401
SC 13G
Jan 15, 2021
jpmorgan chase & co
8.5%
3,340,089
SC 13G

PSNL Fair Value

Personalis fair value in different scenarios

The table shows the Fair Value estimates for Personalis for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.19

-54.23%

1.26

-51.54%

1.39

-46.54%

1.65

-36.54%

1.90

-26.92%
Current Inflation

1.19

-54.23%

1.25

-51.92%

1.37

-47.31%

1.60

-38.46%

1.82

-30.00%
Very High Inflation

1.19

-54.23%

1.24

-52.31%

1.35

-48.08%

1.54

-40.77%

1.73

-33.46%

Historical Personalis Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Personalis

View All Filings
Date Filed Form Type Document
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 08, 2023
8-K
Current Report
Feb 23, 2023
10-K
Annual Report
Feb 23, 2023
8-K
Current Report
Feb 23, 2023
S-8
Employee Benefits Plan

Latest Insider Trading transactions for PSNL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
Tachibana Aaron
sold
-11,164
2.83
-3,945
cfo and coo
2023-03-17
Chen Richard
sold
-3,718
2.83
-1,314
chief medical officer and evp
2023-01-31
Chen Richard
sold
-1,236
2.2
-562
chief medical officer
2023-01-31
Tachibana Aaron
sold
-1,687
2.2
-767
chief financial officer
2022-12-20
Chen Richard
sold
-3,360
1.92
-1,750
chief medical officer
2022-12-20
Tachibana Aaron
sold
-7,378
1.92
-3,843
chief financial officer
2022-12-15
Chen Richard
sold
-17,942
2.5
-7,177
chief medical officer
2022-12-15
Tachibana Aaron
sold
-17,942
2.5
-7,177
chief financial officer
2022-12-15
Moore Stephen Michael
sold
-4,825
2.5
-1,930
general counsel
2022-12-14
West John Stephen
acquired
24,400
2.44
10,000
president and ceo

1–10 of 50

John S. West
330
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

PSNL Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenue$ 65,047$ 85,494$ 78,648
Costs and expenses   
Cost of revenue51,69753,83758,534
Research and development64,91249,31228,568
Selling, general and administrative63,96947,69833,692
Total costs and expenses180,578150,847120,794
Loss from operations(115,531)(65,353)(42,146)
Interest income2,396367949
Interest expense(201)(184)(2)
Other income (expense), net61(42)(24)
Loss before income taxes(113,275)(65,212)(41,223)
Provision for income taxes401457
Net loss$ (113,315)$ (65,226)$ (41,280)
Net loss per share, basic$ (2.48)$ (1.49)$ (1.20)
Net loss per share, diluted$ (2.48)$ (1.49)$ (1.20)
Weighted-average shares outstanding, basic45,704,80543,886,73034,374,903
Weighted-average shares outstanding, diluted45,704,80543,886,73034,374,903

PSNL Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 89,128$ 105,585
Short-term investments78,530181,479
Accounts receivable, net16,64218,468
Inventory and other deferred costs8,5915,610
Prepaid expenses and other current assets6,8087,089
Total current assets199,699318,231
Property and equipment, net61,93519,650
Operating lease right-of-use assets26,48053,822
Other long-term assets4,5864,825
Total assets292,700396,528
Current liabilities  
Accounts payable12,8549,221
Accrued and other current liabilities19,01318,110
Contract liabilities1,2643,982
Total current liabilities33,13131,313
Long-term operating lease liabilities41,04152,797
Other long-term liabilities3892,117
Total liabilities74,56186,227
Commitments and contingencies (Note 12)
Stockholders’ equity  
Common stock, $0.0001 par value - 200,000,000 shares authorized; 46,707,084 and 44,904,512 shares issued and outstanding at December 31, 2022 and 2021, respectively54
Additional paid-in capital579,456557,558
Accumulated other comprehensive loss(912)(166)
Accumulated deficit(360,410)(247,095)
Total stockholders’ equity218,139310,301
Total liabilities and stockholders’ equity$ 292,700$ 396,528